Dhanvantri Jeevan RekhaBOM:531043 -3.50%56 Net Margin % is 4.14% as of Mar. 2026, which is 251% above its 10-year median of 1.18. GuruFocus rates BOM:531043 with a GF Score™ of 56/100 and a GF Value™ of ₹24.87 (Fairly Valued). The stock has 3 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Dhanvantri Jeevan Rekha ranks worse than 57.06% on this metric.
The historical rank and industry rank for Dhanvantri Jeevan Rekha's Net Margin % or its related term are showing as below:
BOM:531043'
s Net Margin % Range Over the Past 10 Years
Min: -14.55 Med: 1.18 Max: 5.27
Current: 1.51
BOM:531043's Net Margin % is ranked worse than 57.06% of 666
companies
in the Healthcare Providers & Services industry
Industry Median: 2.915
vs BOM:531043: 1.51
Dhanvantri Jeevan Rekha (BOM:531043) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Dhanvantri Jeevan Rekha Net Margin % Related Terms
Dhanvantri Jeevan Rekha Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531043 vs HCA, THC, DVA: Net Margin % Comparison
For the Medical Care Facilities subindustry, Dhanvantri Jeevan Rekha's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dhanvantri Jeevan Rekha Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dhanvantri Jeevan Rekha's Net Margin % distribution charts can be found below:
* The bar in red indicates where Dhanvantri Jeevan Rekha's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dhanvantri Jeevan Rekha (BOM:531043) has a Net Margin % of 4.14% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Dhanvantri Jeevan Rekha and its competitors. This is 251% above median its historical median of 1.18. According to the industry distribution chart, Dhanvantri Jeevan Rekha ranks #380 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 57.1%.
Is Dhanvantri Jeevan Rekha's Net Margin % too high?
Dhanvantri Jeevan Rekha's current Net Margin % of 4.14% is 251% above median its 10-year median of 1.18. The Healthcare Providers & Services industry median Net Margin % is 2.92. Dhanvantri Jeevan Rekha's value of 4.14% is 42% above this industry median. Based on the distribution chart, Dhanvantri Jeevan Rekha ranks #380 out of 666 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Dhanvantri Jeevan Rekha has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dhanvantri Jeevan Rekha's Net Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dhanvantri Jeevan Rekha ranks #380 out of 666 companies for Net Margin %. This places Dhanvantri Jeevan Rekha in the lower half of its industry. The industry median Net Margin % is 2.92. Dhanvantri Jeevan Rekha's value of 4.14% is 42% above this benchmark. While the company's 10-year median is 1.18 vs. the industry median of 2.92, Dhanvantri Jeevan Rekha has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.92, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dhanvantri Jeevan Rekha's current Net Margin % of 4.14% is 42% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Dhanvantri Jeevan Rekha and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dhanvantri Jeevan Rekha's current Net Margin % is 4.14%, which is 251% above median its own 10-year median of 1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dhanvantri Jeevan Rekha stock overvalued right now?
Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha (BOM:531043) is currently considered Fairly Valued. The stock's GF Value™ is ₹24.87, compared to a current price of ₹26.45 — trading 6.4% above its estimated fair value. The current Net Margin % is 4.14%, which is 251% above median its 10-year median of 1.18 and 42% above the Healthcare Providers & Services industry median of 2.92. Dhanvantri Jeevan Rekha's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Dhanvantri Jeevan Rekha (BOM:531043), the current Net Margin % is 4.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dhanvantri Jeevan Rekha (BOM:531043) Overvalued in 2026?
Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha stock appears to be overvalued.
The current stock price of ₹26.45 is trading 6.4% above its estimated GF Value™ of ₹24.87.
GuruFocus considers Dhanvantri Jeevan Rekha to be Fairly Valued.
Key valuation signals for BOM:531043:
Net Margin %: 4.14% (251% above median its 10-year median of 1.18)
GF Value™: ₹24.87 vs. price of ₹26.45 (6.4% above fair value)
Industry Position: 42% above the Healthcare Providers & Services median (#380 of 666)
No single metric tells the full story. See the BOM:531043 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dhanvantri Jeevan Rekha Ltd is engaged in providing diagnostic and therapeutic services and has extended its scope of diagnostic and hospital services by providing a fully operational Cath Lab, catering to higher end needs of the cardiac patients including Angiography, Angioplasty, Pacemaker Implantation, Valvuloplasty etc. The hospital has expanded its services to include a wide range of specialties such as Cardiology, Neurology, Orthopedics, Radiology, Gastroenterology, General Surgery, Urology, and General Medicine.
56GF Score
Get the complete analysis for BOM:531043
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531043 has been successfully added to your 
